Humacyte’s (HUMA) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Humacyte (NASDAQ:HUMA) in a research report sent to investors on Tuesday morning,Benzinga reports. The firm currently has a $25.00 target price on the stock.

A number of other equities analysts also recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price (up previously from $12.00) on shares of Humacyte in a research note on Friday, December 20th. BTIG Research reissued a “buy” rating and issued a $10.00 target price on shares of Humacyte in a report on Friday, October 18th. TD Cowen reissued a “buy” rating and issued a $10.00 target price on shares of Humacyte in a research note on Friday, October 18th. Piper Sandler set a $6.00 price target on Humacyte and gave the stock a “neutral” rating in a research report on Friday, October 18th. Finally, Benchmark increased their price objective on shares of Humacyte from $15.00 to $17.00 and gave the company a “buy” rating in a research report on Monday, December 23rd. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Humacyte presently has an average rating of “Buy” and a consensus target price of $13.71.

Humacyte Price Performance

NASDAQ HUMA opened at $4.59 on Tuesday. Humacyte has a twelve month low of $2.80 and a twelve month high of $9.97. The firm has a market capitalization of $577.70 million, a PE ratio of -3.43 and a beta of 1.32. The stock’s 50 day moving average is $4.52 and its 200 day moving average is $5.64.

Humacyte (NASDAQ:HUMA) last announced its quarterly earnings data on Friday, November 8th. The company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.08). During the same quarter last year, the firm earned ($0.25) earnings per share. On average, research analysts anticipate that Humacyte will post -1.27 earnings per share for the current year.

Insider Buying and Selling at Humacyte

In related news, Director Brady W. Dougan sold 427,459 shares of Humacyte stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $4.34, for a total value of $1,855,172.06. Following the completion of the sale, the director now owns 1,992,253 shares of the company’s stock, valued at $8,646,378.02. The trade was a 17.67 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Laura E. Niklason sold 811,172 shares of the stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $4.44, for a total value of $3,601,603.68. Following the completion of the transaction, the chief executive officer now directly owns 2,419,712 shares in the company, valued at approximately $10,743,521.28. This represents a 25.11 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,500,000 shares of company stock worth $6,606,799. Company insiders own 11.20% of the company’s stock.

Institutional Investors Weigh In On Humacyte

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Wealth Effects LLC boosted its holdings in shares of Humacyte by 89.1% in the fourth quarter. Wealth Effects LLC now owns 121,400 shares of the company’s stock worth $613,000 after buying an additional 57,200 shares during the last quarter. SG Americas Securities LLC boosted its stake in shares of Humacyte by 22.0% during the 4th quarter. SG Americas Securities LLC now owns 39,143 shares of the company’s stock worth $198,000 after acquiring an additional 7,069 shares during the last quarter. ACT Wealth Management LLC bought a new stake in shares of Humacyte during the 4th quarter valued at $57,000. ARS Investment Partners LLC increased its stake in shares of Humacyte by 17.8% in the 4th quarter. ARS Investment Partners LLC now owns 99,419 shares of the company’s stock worth $502,000 after purchasing an additional 15,000 shares in the last quarter. Finally, Clarus Wealth Advisors bought a new position in Humacyte in the 4th quarter worth $207,000. Hedge funds and other institutional investors own 44.71% of the company’s stock.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.